{"id":"https://openalex.org/W2592008382","doi":"https://doi.org/10.1182/blood.v114.22.3842.3842","title":"NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells.","display_name":"NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells.","publication_year":2009,"publication_date":"2009-11-20","ids":{"openalex":"https://openalex.org/W2592008382","doi":"https://doi.org/10.1182/blood.v114.22.3842.3842","mag":"2592008382"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v114.22.3842.3842","doi":"https://doi.org/10.1182/blood.v114.22.3842.3842","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.3842.3842","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006765393","display_name":"Dharminder Chauhan","orcid":"https://orcid.org/0000-0002-5548-6138","observed_orcids":["https://orcid.org/0000-0002-5548-6138"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dharminder Chauhan","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102256659","display_name":"Ajita Singh","orcid":"https://orcid.org/0000-0002-6070-4232","observed_orcids":["https://orcid.org/0000-0002-6070-4232"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ajita V. Singh","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009873142","display_name":"Madhavi L. Bandi","orcid":"https://orcid.org/0000-0002-7562-0170","observed_orcids":["https://orcid.org/0000-0002-7562-0170"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Madhavi Bandi","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052048627","display_name":"Noopur S Raje","orcid":"https://orcid.org/0000-0003-3066-1275","observed_orcids":["https://orcid.org/0000-0003-3066-1275"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Noopur Raje","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109183476","display_name":"Robert L Schlossman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert L Schlossman","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110212659","display_name":"George Kenneth Lloyd","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"G. Kenneth Lloyd","raw_affiliation_strings":["Nereus Pharmaceuticals, Inc., San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nereus Pharmaceuticals, Inc., San Diego, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Paul Richardson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000260833","display_name":"Michael A. Palladino","orcid":"https://orcid.org/0000-0002-4687-7612","observed_orcids":["https://orcid.org/0000-0002-4687-7612"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael A. Palladino","raw_affiliation_strings":["Nereus Pharmaceuticals, Inc., San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nereus Pharmaceuticals, Inc., San Diego, CA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth C. Anderson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5009873142","https://openalex.org/A5043526996","https://openalex.org/A5052048627","https://openalex.org/A5110212659"],"corresponding_institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210117453"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.43225659,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"114","issue":"22","first_page":"3842","last_page":"3842"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.8109999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.8109999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.1858000010251999,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vascular-disrupting-agents","display_name":"vascular disrupting agents","score":0.984000027179718},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":1.0},{"id":"https://openalex.org/keywords/angiogenesis-inhibition","display_name":"angiogenesis inhibition","score":0.824999988079071},{"id":"https://openalex.org/keywords/microtubule-disruption","display_name":"microtubule disruption","score":0.878000020980835},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.8989999890327454},{"id":"https://openalex.org/keywords/caspase-activation","display_name":"caspase activation","score":0.7049999833106995},{"id":"https://openalex.org/keywords/cell-cycle-arrest","display_name":"cell cycle arrest","score":0.45899999141693115},{"id":"https://openalex.org/keywords/cell-migration","display_name":"cell migration","score":0.45399999618530273},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.49300000071525574},{"id":"https://openalex.org/keywords/relapsed-multiple-myeloma","display_name":"relapsed multiple myeloma","score":0.6539999842643738},{"id":"https://openalex.org/keywords/tumor-vasculature","display_name":"tumor vasculature","score":0.5600000023841858},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.5619999766349792},{"id":"https://openalex.org/keywords/vascular-endothelial-cells","display_name":"vascular endothelial cells","score":0.5640000104904175}],"concepts":[{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.7331652045249939},{"id":"https://openalex.org/C2778608917","wikidata":"https://www.wikidata.org/wiki/Q6787805","display_name":"Matrigel","level":3,"score":0.7128655910491943},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5954780578613281},{"id":"https://openalex.org/C2780070996","wikidata":"https://www.wikidata.org/wiki/Q61482373","display_name":"Trypan blue","level":3,"score":0.5298126935958862},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5050073266029358},{"id":"https://openalex.org/C88634738","wikidata":"https://www.wikidata.org/wiki/Q24769543","display_name":"Annexin","level":3,"score":0.47484496235847473},{"id":"https://openalex.org/C2778271429","wikidata":"https://www.wikidata.org/wiki/Q1281049","display_name":"Neovascularization","level":3,"score":0.45768964290618896},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.3907770812511444},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3820056915283203},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.3697514533996582},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.36956435441970825},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.3501218557357788},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.3253978490829468},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3018851578235626},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.17489472031593323},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v114.22.3842.3842","doi":"https://doi.org/10.1182/blood.v114.22.3842.3842","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.3842.3842","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2034483653","https://openalex.org/W2042575262","https://openalex.org/W2078977301","https://openalex.org/W2943973648","https://openalex.org/W2968089618","https://openalex.org/W2089410776","https://openalex.org/W2506353506","https://openalex.org/W2912922044","https://openalex.org/W2566653574","https://openalex.org/W2106345790"],"abstract_inverted_index":{"Abstract":[0,1],"3842":[2],"Poster":[3],"Board":[4],"III-778":[5],"Background":[6],"and":[7,20,38,56,70,81,95,101,109,139,165,204,222,268,306,347,476,505,527,571,581,593,604],"Rationale":[8],"Vascular":[9],"disrupting":[10,16,57],"agents":[11],"(VDAs)":[12],"act":[13],"via":[14],"selectively":[15],"established":[17,576],"tumor":[18,119],"vasculature":[19],"have":[21],"shown":[22],"remarkable":[23,525],"clinical":[24],"success":[25],"as":[26,115,117,560],"anti-cancer":[27],"therapies.":[28,128],"NPI-2358":[29,46,85,225,264,316,371,418,447,484,531,550,559,592],"is":[30,254],"a":[31,35,211,229,348,397,494,555,561,577,585],"novel":[32,622],"VDA":[33],"with":[34,224,263,470,483,566,610],"distinct":[36],"structure":[37,152,362],"mechanism":[39],"of":[40,52,65,84,180,217,238,319,337,355,370,403,435,446,472,480,489,508,530,549,558,588,591,620],"action":[41],"from":[42,121,324],"other":[43],"available":[44],"VDAs.":[45],"binds":[47],"to":[48,171,196,256,624],"the":[49,58,79,335,420,428,589,615,618],"colchicine-binding":[50],"site":[51],"beta-tubulin":[53],"preventing":[54],"polymerization":[55],"cytoplasmic":[59],"microtubule":[60],"network,":[61],"thereby":[62],"causing":[63],"loss":[64],"vascular":[66,157],"endothelial":[67,158],"cytoskeletal":[68],"function,":[69],"inducing":[71],"cytotoxicity":[72],"in":[73,86,93,96,146,172,236,252,279,284,356,386,400,411,427,457,538,545,551,564,595,628],"cancer":[74,599],"cells.":[75,540],"Here,":[76],"we":[77],"examined":[78],"anti-angiogenic":[80,178,526],"anti-tumor":[82,528],"activity":[83,346,445,529,548,605],"multiple":[87],"myeloma":[88],"(MM)":[89],"cells":[90,120,159,323,406,437,452,482],"using":[91,134,148,186,194,210,272,359,510],"both":[92],"vitro":[94,147,357],"vivo":[97,173,546],"model":[98],"systems.":[99],"Material":[100],"Methods":[102],"We":[103],"utilized":[104],"MM.1S,":[105,218,294],"MM.1R,":[106,220,298],"RPMI-8226,":[107,219,302],"U266,":[108],"INA-6":[110],"human":[111,156],"MM":[112,122,258,286,322,405,436,533],"cell":[113,240,259,287,597],"lines,":[114],"well":[116],"purified":[118],"patients":[123,325,565],"relapsing":[124],"after":[125],"prior":[126],"anti-MM":[127,345,547],"Cell":[129],"viability/apoptosis":[130],"assays":[131,183,395,430],"were":[132,184,261],"performed":[133,185,193],"MTT,":[135],"trypan":[136],"blue":[137],"exclusion,":[138],"Annexin":[140,273,290],"V/PI":[141,274],"staining.":[142,275],"Angiogenesis":[143],"was":[144,192,208,282,448,468],"measured":[145],"Matrigel":[149,163],"capillary-like":[150,167,360],"tube":[151,168,361],"formation":[153,363,385],"assays:":[154],"Since":[155],"(HUVECs)":[160],"plated":[161],"onto":[162],"differentiate":[164],"form":[166],"structures":[169],"similar":[170,443],"neovascularization,":[174],"this":[175],"assay":[176,364],"measures":[177],"effects":[179],"drugs/agents.":[181],"Migration":[182],"transwell":[187],"insert":[188,394],"assays.":[189],"Immunoblot":[190],"analysis":[191],"antibodies":[195],"caspase-8,":[197,473],"caspase-9,":[198,474],"caspase-3,":[199],"PARP,":[200],"Bcl-2,":[201],"Bax,":[202],"pJNK":[203],"GAPDH.":[205],"Statistical":[206],"significance":[207],"determined":[209],"Student":[212],"t":[213],"test.":[214],"Results":[215],"Treatment":[216],"INA-6,":[221,307],"KMS-12BM":[223],"for":[226,265,270,352,375,425,524,617],"24h":[227],"induces":[228],"dose-dependent":[230],"significant":[231,277,536],"(P":[232],"<":[233,312,331,391,416,460],"0.005)":[234],"decrease":[235,251,456],"viability":[237,253,318,336],"all":[239,285],"lines":[241,260,288],"(IC50":[242,326],"range:":[243,327],"5-8":[244],"nM;":[245,329],"n=3).":[246,314],"To":[247],"determine":[248],"whether":[249],"NPI-2358-induced":[250,280,466,516],"due":[255],"apoptosis,":[257],"treated":[262],"24h;":[266],"harvested,":[267],"analyzed":[269],"apoptosis":[271,281,467],"A":[276,442],"increase":[278],"observed":[283],"(%":[289],"V+/PI-":[291],"apoptotic":[292],"cells:":[293],"48":[295],"\u00b1":[296,300,304,309,408,454],"2.3%;":[297],"46.6":[299],"3.1%;":[301],"61.7":[303],"4.5%;":[305],"59.9":[308],"3.2%;":[310],"P":[311,330,390,415,459],"0.05;":[313],"Importantly,":[315,478,554],"decreased":[317,383],"freshly":[320],"isolated":[321],"3-7":[328],"0.005),":[332],"without":[333,499,535],"affecting":[334,500],"normal":[338,539],"peripheral":[339],"blood":[340],"mononuclear":[341],"cells,":[342,534],"suggesting":[343],"specific":[344],"favorable":[349,578],"therapeutic":[350],"index":[351],"NPI-2358.":[353],"Examination":[354],"angiogenesis":[358],"showed":[365,396,464,600],"that":[366,465],"even":[367],"low":[368],"doses":[369],"(7":[372],"nM":[373,379,424],"treatment":[374,479],"12h;":[376],"IC50:":[377],"20":[378],"at":[380,419],"24h)":[381],"significantly":[382],"tubule":[384],"HUVECs":[387],"(70-80%":[388],"decrease;":[389],"0.05).":[392,417,461],"Transwell":[393],"marked":[398],"reduction":[399],"serum-dependent":[401],"migration":[402,429],"NPI-2358-treated":[404,412],"(42":[407],"2.1%":[409],"inhibition":[410],"vs.":[413],"control;":[414],"concentrations":[421],"tested":[422],"(5":[423,485],"12h)":[426],"did":[431],"not":[432],"affect":[433],"survival":[434],"(>":[438],"95%":[439],"viable":[440],"cells).":[441],"anti-migration":[444],"noted":[449],"against":[450,532],"HUVEC":[451],"(48":[453],"1.7%":[455],"migration;":[458],"Mechanistic":[462],"studies":[463,542],"associated":[469],"activation":[471],"caspase-3":[475],"PARP.":[477],"MM.1S":[481],"nM)":[486],"triggered":[487],"phosphorylation":[488],"c-Jun":[490],"amino-terminal":[491],"kinase":[492],"(JNK),":[493],"classical":[495],"stress":[496],"response":[497],"protein,":[498],"Bcl-2":[501],"family":[502],"members":[503],"Bax":[504],"Bcl-2.":[506],"Blockade":[507],"JNK":[509],"dominant":[511],"negative":[512],"strategy":[513],"markedly":[514],"abrogated":[515],"apoptosis.":[517],"Conclusion":[518],"Our":[519],"preclinical":[520,612],"data":[521],"provide":[522,614],"evidence":[523],"toxicity":[537],"Ongoing":[541],"are":[543],"examining":[544],"animal":[552],"models.":[553],"Phase-1":[556],"study":[557,587],"single":[562],"agent":[563],"advanced":[567],"malignancies":[568],"(lung,":[569],"prostrate":[570],"colon":[572],"cancer)":[573],"has":[574],"already":[575],"pharmacokinetic,":[579],"pharmacodynamic":[580],"safety":[582],"profile;":[583],"and,":[584],"Phase-2":[586],"combination":[590],"docetaxel":[594],"non-small":[596],"lung":[598],"encouraging":[601],"safety,":[602],"pharmacokinetic":[603],"data.":[606],"These":[607],"findings,":[608],"coupled":[609],"our":[611],"studies,":[613],"framework":[616],"development":[619],"NPI-2358-based":[621],"therapies":[623],"improve":[625],"patient":[626],"outcome":[627],"MM.":[629],"Disclosures:":[630],"Chauhan:":[631],"Nereus":[632],"Pharmaceuticals,":[633,637,641,645],"Inc:":[634,642,646],"Consultancy.":[635,647],"Lloyd:Nereus":[636],"In:":[638],"Employment.":[639,643],"Palladino:Nereus":[640],"Anderson:Nereus":[644]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-03-16T00:00:00"}